Acetylcysteine for radiocontrast nephropathy.
Radiocontrast nephropathy may in part be mediated by generation of reactive oxygen species causing direct toxic damage to renal tubular epithelial cell and renal medullary ischemia. Data from experimental studies indicated that antioxidants, eg, acetylcysteine, may prevent radiocontrast-induced nephropathy. Recently, one prospective, randomized, placebo-controlled study in patients with moderate renal insufficiency confirmed that the prophylactic oral administration of acetylcysteine at a dose of 600 mg twice daily along with hydration prevents the reduction in renal function by a nonionic, low-osmolality radiocontrast agent.
Tepel
M
M
Medical Klinik IV, Universitätsklinikum Benjamin-Franklin, Freie Universität Berlin, Germany.
Zidek
W
W
D000111:Acetylcysteine / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D003287:Contrast Media / Q000009:adverse effects*; D016166:Free Radical Scavengers / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000150:complications; D007684:Kidney Tubules / Q000187:drug effects; D017382:Reactive Oxygen Species / Q000494:pharmacology
D003287:Contrast Media; D016166:Free Radical Scavengers; D017382:Reactive Oxygen Species; D000111:Acetylcysteine